Movement Alert｜Twist Bioscience Corp Overnight Decline 6.09%, prior rating initiations and Lilly collaboration remain in focus

Market Focus10-30

On October 30, Twist Bioscience Corp recorded an Overnight fall of 6.09%, trading at $163.81 per share, with turnover of $6,088.63.

The move appears linked to continued market digestion of earlier event-driven catalysts rather than a fresh announcement, with recent attention centered on analyst coverage initiations and the company’s antibody discovery collaboration with Eli Lilly’s TuneLab platform.

Earlier disclosures showed Jefferies initiated coverage with a Hold rating and a $150 price target, while UBS initiated with a Neutral rating and a $144 price target. Separately, Twist Bioscience Corp said it would provide antibody characterization data services to Lilly TuneLab, an AI and machine learning drug discovery platform focused on accelerating antibody drug discovery. Recent market commentary indicated those developments had already lifted visibility, but no stronger new catalyst was evident as funds rotated and volatility increased.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment